About: Management of Thrombotic Complications in COVID-19: An Update

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Management of Thrombotic Complications in COVID-19: An Update Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Management of Thrombotic Complications in COVID-19: An Update
Creator	Lavie, Carl Lavie, J Ball, Somedeb Hajra, Adrija Bandyopadhyay, Dhrubajyoti Chakraborty, Sandipan Aronow, Wilbert Mathai, Sheetal Veyseh, Maedeh Carl, · Dhrubajyoti Bandyopadhyay, · Maedeh Veyseh, · Mathai, Vasundara Sheetal, · Somedeb Ball, ·
source	Medline; PMC
abstract	Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily affects the respiratory tract and causes lung injury characterized by acute respiratory distress syndrome. Although the pathophysiology of COVID-19 is not yet clear, the most widely accepted mechanism is systemic inflammation. A clinically significant effect of the inflammation is coagulopathy. As a result of this effect, patients are found to have a high risk of venous thromboembolism. Studies have reported a high incidence of thrombotic complications in critically ill patients with COVID-19. In this review, we discuss the most updated evidence on the pathophysiology, diagnosis, and treatment of the coagulopathy of COVID-19. Prophylactic anticoagulation is recommended for all in-patients with COVID-19. Those with a higher risk of developing thromboembolic events or who have already developed venous thromboembolism should be treated with therapeutic anticoagulation. We also discuss post-discharge prophylaxis for high-risk patients and some newly proposed treatments for the hypercoagulability that could improve the outcomes of the affected patients.
has issue date	2020-08-16(xsd:dateTime)
bibo:doi	10.1007/s40265-020-01377-x
bibo:pmid	32803670
has license	no-cc
sha1sum (hex)	7db6739d5ba1393695a35fd6816cd24783ac20b3
schema:url	https://doi.org/10.1007/s40265-020-01377-x
resource representing a document's title	Management of Thrombotic Complications in COVID-19: An Update
has PubMed Central identifier	PMC7429134
has PubMed identifier	32803670
schema:publication	Drugs
resource representing a document's body	covid:7db6739d5ba1393695a35fd6816cd24783ac20b3#body_text
is schema:about of	named entity 'coagulopathy' named entity 'Complications' named entity 'RISK OF' named entity 'PATHOPHYSIOLOGY' named entity 'HAVE' named entity 'CHARACTERIZED' named entity 'EFFECT' named entity 'DISCUSS' named entity 'Coronavirus disease 2019' named entity 'coagulopathy' named entity 'high risk' named entity 'lung injury' named entity 'patients' named entity 'venous thromboembolism' named entity 'COVID-19' named entity 'patients' named entity 'Studies' named entity 'Prophylactic' named entity 'pathophysiology' named entity 'Management' named entity 'significant effect' named entity 'COVID' named entity 'respiratory tract' named entity 'hypercoagulability' named entity 'thrombotic complications' named entity 'COVID' named entity 'higher risk' named entity 'Coronavirus disease 2019' named entity 'thromboembolic events' named entity 'Thrombotic Complications' named entity 'COVID-19' named entity 'ARDS' named entity 'LDH' named entity 'Thrombosis' named entity 'd-dimer' named entity 'intravenous thrombolysis' named entity 'UFH' named entity 'heparin induced thrombocytopenia' named entity 'tissue factor' named entity 'epithelium' named entity 'COVID' named entity 'COVID' named entity 'early diagnosis' named entity 'coronary circulation' named entity 'low-molecular-weight heparin' named entity 'd-dimer' named entity 'subcutaneous' named entity 'hepatic' named entity 'alveolar' named entity 'VTE' named entity 'pathogen-associated molecular patterns' named entity 'VTE' named entity 'nafamostat' named entity 'acute myocardial infarction' named entity 'anti-platelet' named entity 'acute medical' named entity 'extracorporeal membrane oxygenation' named entity 'treatment options' named entity '2, 3' named entity 'coagulation cascade' named entity 'hypercoagulability' named entity 'coagulopathy' named entity 'endothelium' named entity 'CTPA' named entity 'thrombosis' named entity 'stroke' named entity 'Heparin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software